News

Privia Health Enters Arizona In Partnership with Integrated Medical Services

IMS is One of the Largest Independent Multi-Specialty Practices in the State Arizona Represents 15th State in National Primary Care-Centric…

9 months ago

IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8’s…

9 months ago

Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial

SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel…

9 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects…

9 months ago

Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction…

9 months ago

Arialief Supplement: Vitamins Reviews and Complaints for Neuropathic Pain

HONOLULU, April 09, 2025 (GLOBE NEWSWIRE) -- Arialief is a premium dietary supplement specifically designed to target the root causes…

9 months ago

Glass House Brands Announces Hemp Research and Development Agreement with the University of California, Berkeley

LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…

9 months ago

M6P Therapeutics to Host Virtual KOL Event to Discuss the Lysosomal Storage Disorders Treatment Landscape on April 22, 2025

Discussions will focus on Pompe Disease and M6P’s S1S3 Co-expression Platform TechnologyST. LOUIS, Mo., April 09, 2025 (GLOBE NEWSWIRE) --…

9 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in…

9 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

NDA Submission Anticipated Q2 Calendar 2025PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics…

9 months ago